Invivyd, Inc. (IVVD)
NASDAQ: IVVD · Real-Time Price · USD
0.444
+0.014 (3.30%)
At close: Dec 20, 2024, 4:00 PM
0.430
-0.014 (-3.11%)
After-hours: Dec 20, 2024, 6:23 PM EST
Invivyd Employees
As of December 31, 2023, Invivyd had 95 total employees, including 94 full-time and 1 part-time employees. The number of employees increased by 9 or 10.47% compared to the previous year.
Employees
95
Change (1Y)
9
Growth (1Y)
10.47%
Revenue / Employee
$121,726
Profits / Employee
-$2,369,853
Market Cap
53.10M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 95 | 9 | 10.47% |
| Dec 31, 2022 | 86 | -17 | -16.50% |
| Dec 31, 2021 | 103 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| CareCloud | 3,600 |
| Xtant Medical Holdings | 215 |
| Repare Therapeutics | 179 |
| Celularity | 120 |
| Mural Oncology | 117 |
| Connect Biopharma Holdings | 81 |
| Shattuck Labs | 75 |
| Spero Therapeutics | 46 |
IVVD News
- 5 weeks ago - Invivyd, Inc. (IVVD) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewsWire
- 5 weeks ago - Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor - GlobeNewsWire
- 5 weeks ago - Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Uploaded to MedRxiv and BioRxiv, Respectively - GlobeNewsWire
- 6 weeks ago - Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference - GlobeNewsWire
- 6 weeks ago - Invivyd to Host Third Quarter 2024 Financial Results and Corporate Update Conference Call on November 14, 2024 - GlobeNewsWire
- 7 weeks ago - Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term Profitability - GlobeNewsWire
- 7 weeks ago - Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA™ (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent Participants - GlobeNewsWire